DermaSensor Inc

DermaSensor Inc manufactures the DermaSensor device, an FDA-cleared, handheld optical spectroscopy system for non-invasive skin cancer detection at the point of care. The device uses elastic scattering spectroscopy (ESS) combined with proprietary artificial intelligence algorithms to analyze suspicious skin lesions and deliver malignancy risk assessment in approximately 30 seconds. Clinical data indicates 96% accuracy in detecting the three most common skin cancers: melanoma, basal cell carcinoma, and squamous cell carcinoma. The technology is designed for primary care physicians, family medicine practitioners, internal medicine doctors, plastic surgeons, and health systems seeking to improve skin cancer screening and reduce diagnostic uncertainty before dermatology referral. The device comprises a handheld probe that records five spectral recordings from the lesion; an integrated computer analyzes light scattering patterns to provide an "Investigate Further" or "Monitor" risk output. DermaSensor has completed 15 development, validation, and clinical utility studies encompassing over 5,000 diagnosed lesions. The company offers a 90-day introductory trial program, reimbursement guidance through partnership with The Reimbursement Group (TRG), e-learning training courses, cloud storage, remote device monitoring, and on-demand customer support. FDA 510(k) clearance and Breakthrough Device designation underscore regulatory validation. Markets served include family medicine practices, concierge services, internal medicine, health systems, and walk-in clinics across the United States.